Nurix Therapeutics (NRIX) said Thursday the US Food and Drug Administration has granted Fast Track designation for NX-5948 to treat adults with relapsed or refractory Waldenstrom's macroglobulinemia after at least two lines of therapy.
Fast Track designation is intended to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need, the company said.
Waldenstrom's macroglobulinemia is a rare, slow growing type of non-Hodgkin's lymphoma in which normal bone marrow cells are replaced by malignant lymphocytic cells, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments